HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT06842992

A Phase II Study to Evaluate NH102 for Depression

This study evaluated the safety and effectiveness of NH102 for people with depression.

Medication studyAges 18–65China
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NH102 for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Hefei and 23 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateStarted: December 4, 2024
Recruitment status
Completed
Enrollment listed in the registry
243
Sponsor
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT06842992
Official title
Show the full official title

A Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Dose-exploration Phase II Clinical Trial to Evaluate the Efficacy and Safety of NH102 in the Treatment of Depression

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Hefei · Beijing · Chongqing

20 more locations
  • Xiamen
  • Guangzhou
  • Shenzhen
  • Baoding
  • Xinxiang
  • Zhumadian
  • Changsha
  • Suzhou
  • Wuxi
  • Nanchang
  • Siping
  • Jinan
  • Shanghai
  • Taiyuan
  • Xi’an
  • Chengdu
  • Tianjin
  • Hangzhou
  • Huzhou
  • Ningbo
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NH102 for people with depression.

Who is behind this study?

The study sponsor is Jiangsu Nhwa Pharmaceutical Co., Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including NH102, Duloxetine Hydrochloride Enteric-coated Capsule and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies